FORTISNSEFortis Healthcare Limited· MiscellaneousMinimalNeutral
Announced Fri, 22 May · 20:45 IST

Fortis Healthcare Limited has informed the appointment of cost auditors

FORTIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.5%1-day move
₹961.90
prior close
₹969.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.6+1.3+1.5+0.9+0.5+0.0-2.6-3.4-3.0-2.2+0.8-0.9-2.0
Up moveDown movePending
AI summary

Fortis Healthcare reported strong FY 2025-26 consolidated results with revenue from operations of ₹91,278 lakhs, up 17% from ₹77,828 lakhs in the previous year. Net profit jumped 31% to ₹10,642 lakhs from ₹8,094 lakhs, while EBITDA rose 29% to ₹21,356 lakhs. EPS improved to ₹13.80 from ₹10.26. The Board recommended a final dividend of ₹1 per equity share (10% on ₹10 face value), subject to shareholder approval. M/s Jitender, Navneet & Co. was appointed as Cost Auditor for FY 2026-27. The auditors issued an unmodified opinion, though the report highlighted ongoing SFIO investigation regarding alleged improper transactions originating prior to 2018 and Supreme Court-directed forensic audit for RHT Health Trust transactions.

Likely market impact

Strong operational performance with double-digit growth across revenue, profits, and margins is positive for shareholders. The modest ₹1 dividend provides direct returns. However, the ongoing regulatory investigations and exceptional items totaling ₹2,224 lakhs loss (net) may create some investor caution despite clean audit opinion.